



CytoTools AG: DermaPro® receives market approval in India – a milestone for the development of the company

- *DermaPro® approved for the diabetic foot indication - with a proviso*
- *DermaPro® was developed in Germany and is patented in the world's most important markets*
- *First approval for an active substance of the CytoTools AG worldwide*

Darmstadt, 24th March 2017 – The wound healing agent DermaPro® from the CytoTools subsidiary DermaTools Biotech GmbH has been granted market approval for the indication diabetic foot in India, under the proviso that the active substance production is carried out in India. The DermaTools GmbH reported that Centaur Pharmaceuticals Pvt. Ltd., Mumbai, the Indian license and cooperation partner, has been granted the approval and confirmation for the production of DPOCL, the active substance molecule, as well as final application formulation for marketing, by the Indian authority, Drug Controller General of India (DGCI). The application for this approval was already submitted to the Indian authorities three years ago, after the Indian partner, Centaur, had carried out a phase III trial with 310 patients, confirming the excellent efficacy of DermaPro®: Already after 10 weeks, the wound surfaces of 92 % of the patients had at least been reduced by half, i.e., a continuing healing process had been initiated. For 76% of the patients, after 10 weeks, a complete closure of the chronic wounds was achieved. Furthermore, the healing process took place much faster than the patients in the control group treated with best care.

According to a study by the International Diabetes Federation, worldwide, there are about 420 million diabetics, of these, about 20 % will develop diabetic foot syndrome as the disease progresses. By 2035, the number of diabetics could increase again by about half. In India alone, currently, about 80 million patients are affected. The disease begins with circulatory disorders and narrowing blood vessels and, as the disease develops, damage to the feet occurs and nerves die. The dead nerves result in a reduced pain sensitivity, therefore wounds on the feet are often noticed, and subsequently treated, too late. Up to now, there was no effective healing treatment worldwide. If an infection of the wound occurs, then amputation of the affected area is often the final outcome. According to the journal *klinik*, the treatment of diabetic foot lesions in industrial countries involves estimated costs of between about 6 - 9% of total health expenditure.

CEO and co-founder of the Cytotools AG, Dr. Mark-André Freyberg, is very pleased with the news of the market approval of DPOCL in India: He commented, „We are now at the end of a long, difficult and successful development process. Indeed DermaPro® is one of the first medications which has been completely discovered, developed and brought to market launch by a biotechnology enterprise from Germany. Because of the excellent efficacy and tolerance profile of DermaPro® shown in the trials to date, we assume that further approvals in other indications will follow for the active substance. Also, acutely infected wounds are coming into focus now.”

PRESS RELEASE



CytoTools

With this market authorisation, preparations begin for the Indian market launch. There, after setting up the local production, and after the usual controls by the responsible authorities, the active substance will be produced under the name Woxheal® by Centaur Pharmaceuticals Pvt. Ltd. and, will be placed by them on the market in the final formulation and dosage. The active substance is spread onto the wound directly from the dressing. Thus, for the first time, a highly efficient medication is available for treating chronic wounds, in particular diabetic foot syndrome.

This press release contains specific future oriented statements. These reflect the opinion of *CytoTools* on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (57%) and CytoPharma GmbH (42%).

Contact:

CytoTools AG

Dr. Mark-André Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de